Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 768,323
  • Shares Outstanding, K 68,417
  • Annual Sales, $ 0 K
  • Annual Income, $ -215,790 K
  • EBIT $ -232 M
  • EBITDA $ -241 M
  • 60-Month Beta 1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.96

Options Overview Details

View History
  • Implied Volatility 72.89% ( -53.58%)
  • Historical Volatility 51.11%
  • IV Percentile 10%
  • IV Rank 12.76%
  • IV High 322.09% on 12/01/23
  • IV Low 36.44% on 10/01/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 631
  • Open Int (30-Day) 1,846

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.73
  • Number of Estimates 6
  • High Estimate -0.68
  • Low Estimate -0.78
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +5.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.57 +4.87%
on 11/19/24
12.97 -14.53%
on 11/11/24
-0.27 (-2.33%)
since 10/21/24
3-Month
9.84 +12.65%
on 08/28/24
12.97 -14.53%
on 11/11/24
+0.81 (+7.94%)
since 08/21/24
52-Week
4.92 +125.30%
on 05/29/24
12.97 -14.53%
on 11/11/24
+0.65 (+6.28%)
since 11/21/23

Most Recent Stories

More News
Insider Sale: Chief Medical Officer of $REPL (REPL) Sells 7,246 Shares

Konstantinos Xynos, the Chief Medical Officer of $REPL ($REPL), sold 7,246 shares of the company on 11-18-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

REPL : 11.11 (-1.07%)
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

REPL : 11.11 (-1.07%)
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

REPL : 11.11 (-1.07%)
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL : 11.11 (-1.07%)
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

REPL : 11.11 (-1.07%)
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL : 11.11 (-1.07%)
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

This billionaire-guided hedge fund went bargain-shopping in the second quarter.

AFMD : 2.72 (+1.47%)
CERS : 1.6750 (+0.90%)
REPL : 11.11 (-1.07%)
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous...

REPL : 11.11 (-1.07%)
Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

REPL : 11.11 (-1.07%)
Replimune Announces the Departure of Jason Rhodes from its Board of Directors

WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

REPL : 11.11 (-1.07%)

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United...

See More

Key Turning Points

3rd Resistance Point 11.97
2nd Resistance Point 11.63
1st Resistance Point 11.43
Last Price 11.11
1st Support Level 10.89
2nd Support Level 10.55
3rd Support Level 10.35

See More

52-Week High 12.97
Last Price 11.11
Fibonacci 61.8% 9.89
Fibonacci 50% 8.94
Fibonacci 38.2% 8.00
52-Week Low 4.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar